RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GORI S
Collezione AOU Novara

Items : 10

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.

2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Porzio G; Tiseo M; Russano M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Metro G; Migliorino MR; Passiglia F; Ricciardi S; Zoratto F; Pecci F; Di Marino P; Mansueto G; De Tursi M; Tuzi A; Gori S; Della Gravara L; Macerelli M; Rastelli F; Chiari R; Gelibter A; Marchetti P; Antonuzzo L; Mazzoni F; et alii...

Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ?50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. in Thoracic cancer / Thorac Cancer. 2022 Feb;13(3):483-488. doi: 10.1111/1759-7714.14256. Epub 2021 Dec 22.

2022
AOU Novara

Banna GL; Tiseo M; Cortinovis DL; Facchinetti F; Aerts JGJV; Baldessari C; Giusti R; Bria E; Grossi F; Berardi R; Morabito A; Catino A; Genova C; Mazzoni F; Gelibter A; Rastelli F; Macerelli M; Chiari R; Gori S; Mansueto G; Citarella F; Cantini L; Rijavec E; Bertolini F; Cappuzzo F; De Toma A; Friedlaender A; Metro G; Pensieri MV; et alii...

Corrigendum: Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors. in Frontiers in oncology / Front Oncol. 2022 Feb 2;12:851999. doi: 10.3389/fonc.2022.851999. eCollection 2022.

2022
AOU Novara

Caprara G; Tieri M; Fabi A; Guarneri V; Falci C; Dieci MV; Turazza M; Ballardini B; Bin A; Cinieri S; Vici P; Montagna E; Zamagni C; Mazzi C; Modena A; Marchetti F; Verzè M; Ghelfi F; Titta L; Nicolis F; Gori S;

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Addeo A; Friedlaender A; Banna GL; Di Maio M; Spinelli GP; Russo A; Adamo V; De Filippis M; Metro G; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Buti S; Minuti G; Nigro O; Cantini L; Bracarda S; Citarella F; Russano M; Filetti M; Zoratto F; Gori S; De Tursi M; Mansueto G; Rocco D; et alii...

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. in Journal of translational medicine / J Transl Med. 2021 Jun 24;19(1):270. doi: 10.1186/s12967-021-02937-9.

2021
AOU Novara

Santini D; Zeppola T; Russano M; Citarella F; Anesi C; Buti S; Tucci M; Russo A; Sergi MC; Adamo V; Stucci LS; Bersanelli M; Mazzaschi G; Spagnolo F; Rastelli F; Giorgi FC; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Siringo M; Ferrari M; Marconcini R; Vitale MG; Nicolardi L; Chiari R; Ghidini M; Nigro O; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cortellini A; Mazzaschi G; Tiseo M; Pinato DJ; Carmisciano L; Ficorella C; Porzio G; Cannita K; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Adamo V; Russo A; Olmetto E; Metro G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Minuti G; Tuzi A; Bisonni R; Follador A; Gelibter A; Siringo M; Signorelli D; De Toma A; Garassino MC; et alii...

Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors. in Frontiers in oncology / Front Oncol. 2021 Nov 1;11:705927. doi: 10.3389/fonc.2021.705927. eCollection 2021.

2021
AOU Novara

Correction to: Standard (8?weeks) vs long (12?weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). in BMC cancer / BMC Cancer. 2020 Feb 17;20(1):128. doi: 10.1186/s12885-020-6632-y.

2020
AOU Alessandria
AOU Novara

Numico G; Franzone P; Priora F; Fusco V; Rossi M; Traverso E; Ercolani G; Cavaliere D; Solaini L; Torri V; Ceccarelli C; Balestri R; Buccianti P; Baroffio P; Gentilli S; Coratti A; Menegatti B; Perna F; Rosati R; Delpini R; Mammano E; Elmore U; Contardo T; Perinotti R; Morpurgo E; De Nisco C; Pulighe F; Pernazza G; Boni L; et alii...

Standard (8?weeks) vs long (12?weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). in BMC cancer / BMC Cancer. 2019 Dec 16;19(1):1215. doi: 10.1186/s12885-019-6271-3.

2019
AOU Alessandria
AOU Novara

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. in PloS one / PLoS One. 2015 Sep 4;10(9):e0136731. doi: 10.1371/journal.pone.0136731. eCollection 2015.

2015
ASL Cuneo 1
AOU Novara

Gamucci T; Barni S; Evangelisti L; Saracchini S; Amaducci L; Frassoldati A; Garrone O; Fabi A; Santini D; Vici P; Cretella E; Bria E; Saggia C; Cavanna L; Spazzapan S; Bisagni G; Iezzi L; De Simone V; Duranti S; Turazza M; Cavazzini MG; Gubiotti M; Pinotti G; Gulisano M; Ferro A; Foglietta J; Fiorio E; Inno A; Gori S; et alii...